Background: Sacubitril/valsartan has been shown to improve outcomes in patients with heart failure with reduced ejection fraction (HFrEF). However, initiation of sacubitril/valsartan has primarily been studied in stable, ambulatory patients with HFrEF.
Objective: The objective of this study was to determine risk factors for intolerance to inpatient sacubitril/valsartan initiation.